

## UPL Limited

July 05, 2024

Facilities/Instruments	Amount (₹ crore)	Rating <sup>1</sup>	Rating Action
Long Term / Short Term Bank Facilities	1,650.00	CARE AA+; Negative / CARE A1+	Reaffirmed
Short Term Bank Facilities	850.00	CARE A1+	Reaffirmed
Commercial Paper	1,100.00	CARE A1+	Reaffirmed

Details of instruments/facilities in Annexure-1.

### Rationale and key rating drivers

The ratings assigned to the bank facilities and commercial paper (CP) issue of UPL Ltd. (UPL) continue to derive strength from extensive experience of the promoters in the crop protection value chain and their demonstrated track record of growing the business, organically and inorganically; the strong market position in the global agrochemical industry with presence in all large agriculture cultivating geographies; and the comprehensive product portfolio covering agrochemicals and bio-solutions to post-harvest products. The ratings also factor the increasing focus of the company on differentiated and sustainable agri-solutions, which will be the primary driving force for revenue and profits, going forward.

The ratings, however, continue to be constrained by significant moderation in UPL's performance in FY24 (refers to the period April 1 to March 31) marked by decline in its profitability on the back of global destocking with oversupply leading to lower demand and pricing pressure along-with high amount of rebates, weakening of its leverage and debt coverage indicators on the back of rise in its working capital requirement, strong competition from China and exposure to the inherent risks in the agrochemical industry.

The reaffirmation continues to factor decline in operating performance in FY24 whereby UPL's operating profitability dropped sharply to 10.16% in FY24 from 18.96% in the previous fiscal. However, Q4FY24 showed improvement, with operating margin recovering sequentially to 13.1%. Its PBILDT in Q1FY25 is envisaged to be sequentially better than Q4FY24. With expected recovery in global & domestic demand and subsiding of impact of channel destocking in H1FY25, its operating profitability is expected to improve further from H2FY25 onwards.

With decline in operating profitability in FY24 and stretched working capital cycle, its gross debt level had gone up to Rs.36,173 crore as on December 31, 2023 which, however, declined to Rs.29,336 crore as on March 31, 2024 with improvement in performance in Q4FY24. Accordingly, its debt coverage indicators as reflected from its Net debt/PBILDT which had worsened to 10.22 times as on December 31, 2023, improved to 5.29 times as on March 31, 2024. Going forward, timely rights issue of USD 400 million planned for FY25, monetization plans on business verticals and improvement in cashflows from H2FY25 is expected to help the company to deleverage. Its liquidity is expected to be further supported by no significant fixed debt repayments until Q2FY26. However, ability of UPL to improve its operating performance by end H1FY25 as envisaged will remain a key rating monitorable.

### Rating sensitivities: Factors likely to lead to rating actions

#### Positive factors

- Net Debt/PBILDT below 1.0x on a sustained basis
- Demonstrating strong growth in its scale of operations and earning PBILDT margins above 20%-22% on a sustained basis, along with healthy cash generation.

#### Negative factors

- Continued weak operating performance resulting in interest coverage lower than 2x during H1FY25.
- Significant delay in the equity fund raising or lower cash generation leading to weakening of its liquidity or deterioration in its Net Debt/PBILDT beyond 2.5x on a sustained basis.

### Analytical approach: Consolidated

For arriving at the ratings, CARE Ratings has considered the abridged consolidated financial statements of UPL as published on the stock exchanges for FY24. UPL has various subsidiaries, these companies are consolidated due to the operational synergies and financial linkages between the parent and subsidiaries, fungible cash flows, common management, and support provided by UPL to various subsidiaries. List of entities consolidated with UPL is mentioned in **Annexure-6**

<sup>1</sup>Complete definition of the ratings assigned are available at [www.careedge.in](http://www.careedge.in) and other CARE Ratings Ltd.'s publications

## Outlook: Negative

CARE Ratings Ltd. (CARE Ratings) believes that though there could be improvement in UPL's performance in FY25 over FY24, its business and financial risk profile may remain under pressure in the near term owing to the unprecedented challenges faced by the agrochemical industry, especially if the pace of recovery is slower than envisaged.

## Detailed description of the key rating drivers:

### Key strengths

**Strong market position in agrochemical industry:** UPL is a leading global player in agricultural solutions and the fourth-largest seed manufacturer. Transitioning from a generic post-patent agrochemical company, UPL now offers high-margin, differentiated crop protection and bio-solutions. UPL's strategy focuses on providing sustainable products, reflecting the growing environmental consciousness. With over 750 R&D professionals across more than 20 global centres, UPL invests around 3% of its annual revenue in R&D. Around 80% of its new products are differentiated and sustainable solutions. The business risk profile remains healthy, aided by a portfolio of ~14,326 registrations, 1,552 product formulations and 1,500 patents.

**Extensive experience of promoters:** UPL was incorporated in 1969 and has a successful track record of more than 50 years in the industry. It is promoted by RD Shroff, Ex Chairman & Managing Director, who has more than 50 years of experience in the field. He has retired from the position and now serves as the Chairman Emeritus. His sons, Jai Shroff, Chairman & Global CEO of the group; and Mr. Vikram Shroff, Vice Chairman & Co CEO have vast experience in the industry. The top management is ably supported by a professional senior management team managing the day-to-day operations of the company.

UPL, over the past 25 years, has made 40+ acquisitions and has been successful in accelerating growth in a profitable manner. UPL's strategy to enter new geographies or new products is to acquire companies that are already present in the segment and have a significant market share.

**Wide geographical presence and product portfolio:** UPL has a presence in around 138 countries, thereby strengthening its global positioning and de-risking the business from excessive dependence on any single region. It has 45 manufacturing facilities spread across the globe. The company is present across the crop lifecycle, from seeds, seed-treatment products, pre- and post-harvest products, to storage-treatment products.

**Recovery in performance in Q4FY24 along with reduction in debt level:** UPL's performance was significantly impacted in FY24, especially during 9MFY24, which led to a sharp decline in its operating profit (PBILDT) margins to 10.16% in FY24 compared to 18.96 % in FY23. However, it improved marginally in Q4FY24 with operating margin recovering to 13.1%. Its gross margins in Q1FY25 is envisaged to be sequentially better than Q4FY24. With expected recovery in global & domestic demand and subsiding of impact of channel destocking in H1FY25, its operating profitability is expected to improve further from H2FY25 onwards. The company has undertaken USD 100 million cost reduction initiatives over the next two years, with 50% realized in FY24. UPL cost reduction initiatives yielded results, as the company reduced SG&A expense by 19% YoY in Q3FY24. UPL was able to reduce SG&A expenses by USD 100 million in FY25

With decline in operating profitability in FY24 and stretched working capital cycle, its gross debt level had gone up as on December 31, 2023 which, however, declined by end-FY24 with improvement in performance in Q4FY24. Accordingly, its debt coverage indicators as reflected from its Net debt/PBILDT which had worsened to 10.22 times as on December 31, 2023, improved to 5.29 times as on March 31, 2024. Going forward, timely equity fund raising and improvement in cashflows from H2FY25 is expected to help the company to deleverage further.

### Liquidity: Strong

Despite weakened operating performance resulting in negative gross cash accruals in FY24, UPL maintains a robust liquidity position. As of March 31, 2024, the company holds substantial cash & cash equivalents of Rs.6,247 crore. Until September 2025, UPL has no significant long-term debt repayment obligations. Nevertheless, in FY26 and FY27, the company faces large term debt repayment obligations of Rs.6,000 – 7,000 crore p.a., necessitating partial refinancing. Additionally, UPL's perpetual bonds will be repriced at prevailing market rates in May 2025, potentially resulting in slightly higher interest outgo on these bonds. The company is also expected to come out with its rights issue in FY25 to deleverage the balance sheet and maintain cash at around Rs.4,000-6,000 crore as articulated by its management. UPL's liquidity also derives comfort from low average utilisation of its consortium working capital limits at around 36% during the 12 months period ending April 2024, which provides sufficient headroom in case of exigencies.

CARE Ratings believes that cashflow generated from operations, money raised through rights issue or stake sales along-with its available liquidity would be adequate to meet its debt repayment obligations although larger instalments can entail partial refinancing. In this regard, CARE Ratings continues to draw comfort from UPL's ability to arrange timely refinancing from debt/capital market at competitive rates.

## Key weaknesses

**Significant moderation in performance in FY24 which is expected to recover only gradually:** UPL's performance declined significantly in FY24, with consolidated revenue recording de-growth of 19.5% Y-o-Y in FY24. The decline was on account of channel destocking and pricing pressure in the post-patent space. Inline, the operating profitability dropped sharply to 10.16% in FY24 from 18.96% in the previous fiscal, impacted by rebates and higher inventory carrying cost. Revenue also suffered due to herbicide price erosion in North America and LATAM, driven by increased supplies from China at cheap prices, potentially threatening market share. However, Q4FY24 showed some improvement, with operating margin partially recovering and expected to further improve on a sequential basis in H1FY25. Care Ratings expects UPL's operating profitability to recover on a y-o-y basis in FY25 though expected to be still lower than those witnessed in FY23 as recovery is likely to be gradual. Further, the likely revival of the industry from H2FY25 onwards on account of continued China+1 policy coupled with a significant number of agrochemical products going off-patent augurs well for UPL with more opportunities to introduce their products across global markets.

**High working capital intensity of operations:** UPL faces an extended receivable period due to credit extended to dealers and channel partners across different regions. Payment terms vary by region, with receivable cycles ranging from 90 days to 360 days (particularly in LATAM). UPL's widespread presence necessitates maintaining sufficient stock, leading to longer inventory-holding period as well. However, the company's efforts to diversify manufacturing locations partially mitigate this. In FY24, the working capital cycle increased by 31 days to 126 days due to higher inventory days. These elevated inventory levels also suggest channel destocking, as North American, European, and Brazilian farmers awaited further price decreases, influenced by China's resurgence and lower prices.

**Exposure to risks inherent in agrochemical industry, and competition from China:** The crop-protection sector remains susceptible to various environmental rules and regulations in different countries. UPL sells its products in more than 138 countries across the world, with production units spread in 45 locations. Considering the nature of the product usage, registration, consequent environmental impacts, etc, UPL is required to comply with various local laws, rules, and regulations and operate under a strict regulatory environment. Furthermore, the sector is highly dependent on farm income and monsoon levels. Thus, the infringement of any of the laws and any significant adverse change in the regulatory policies or distribution of monsoon can have a consequence on the operations of the company.

Further, UPL's EBITDA which previously gained substantial advantages from vertical integration due to its extensive production capacity, has faced challenges due to manufacturing overcapacity in China. The recent surge in chemical production capacity in China has led to an excess supply of products globally. Capacity increase from Chinese manufacturers can potentially hamper UPL's growth which remains a key monitorable.

## Environment, social, and governance (ESG) risks

The agrochemical sector significantly affects the environment due to its high greenhouse gas emissions, water consumption, and substantial hazardous waste production from core operations. Additionally, the sector has social implications, impacting the health and well-being of its workforce and local communities due to the nature of its activities.

UPL has undertaken various initiatives and efforts towards mitigating its environmental and social impact and strengthening its ESG profile.

## Key ESG Highlights:

### Environmental Risks

- UPL focuses on reducing greenhouse gas emissions and minimizing its carbon footprint through sustainable practices in manufacturing with investments in renewable energy which has helped UPL to reduce CO2 equivalent emissions by 1.25 lakh tonnes annually.
- UPL achieved Zero Liquid Discharge (ZLD) in its technicals manufacturing facility, a significant milestone in water management with water consumption in UPL's plant decreasing by 40% over the past three years.
- UPL has embraced renewable energy, accounting for 30% of its global power consumption. A solar-wind hybrid farm with a capacity of 61 megawatts (33 MW wind and 28 MW solar) is being established in collaboration with Clean Max.

### Social

- UPL Khedut Pragati in India is maximizing benefits to the farmers from the available resources through Agriculture Development Initiative. 10,000+ farmers are engaged through various agriculture programmes.
- UPL Narmada Project - Develop the agri value chain through interventions with Farmer Producer Organization (FPOs) in the aspirational district of India to impact 10,000 tribal farmers across 100 villages of Narmada district.

### Governance

- UPL's governance structure is characterised by majority of its Board of Directors comprising independent directors, and extensive disclosures. Company has 5 independent directors (50% of the total 10 directors) with one-woman independent director among them.

### Applicable criteria

[Definition of Default](#)

[Liquidity Analysis of Non-financial sector entities](#)

[Rating Outlook and Rating Watch](#)

[Manufacturing Companies](#)

[Financial Ratios – Non financial Sector](#)

[Pesticides & Agrochemicals](#)

[Short Term Instruments](#)

[Consolidation](#)

[Fertilizer](#)

### About the company and industry

#### Industry classification

Macro Economic Indicator	Sector	Industry	Basic Industry
Commodities	Chemicals	Fertilizers & Agrochemicals	Pesticides & Agrochemicals

UPL (erstwhile known as United Phosphorus Limited) is the flagship company of the UPL group, which has emerged as one of the leading agrochemical companies in the world, with a widespread presence across the globe through various subsidiaries. It has a track record of more than 50 years and is promoted by RD Shroff and family. The group has presence in various segments, including seeds, crop protection products, intermediates, specialty chemicals, and other industrial chemicals. UPL's growth strategy is built around filing its own registrations globally and acquiring products and companies to increase its market access and having a strong and cost-efficient supply chain.

Brief Financials (Consolidated) (₹ crore)	FY22 (A)	FY23 (A)	FY24 (Abr.)
Total operating income	46,223	53,520	42,915
PBILDT	9,521	10,146	4,361
PAT (Net Losses)	4,435	4,414	(1,878)
Overall gearing (times)	0.91	0.67	0.90
Interest coverage (times)	4.15	3.42	1.13

A: Audited; Abr.: Abridged; Note: the above results are latest financial results available

Financials are classified as per CARE Ratings' standards

**Status of non-cooperation with previous CRA:** Not applicable

**Any other information:** Not applicable

**Rating history for last three years:** Please refer Annexure-2

**Covenants of rated instrument / facility:** Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

**Complexity level of various instruments rated:** Annexure-4

**Lender details:** Annexure-5

**Annexure-1: Details of instruments/facilities**

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Commercial Paper-Commercial Paper (Standalone)	INE628A14HQ4	Not Available	Not Available	16-08-2024	125.00	CARE A1+
	INE628A14HR2			29-08-2024	150.00	
	INE628A14HS0			04-12-2024	150.00	
	-	Proposed		675.00		
Fund-based - LT/ ST-Cash Credit		-	-	-	1650.00	CARE AA+; Negative / CARE A1+
Non-fund-based-Short Term		-	-	-	850.00	CARE A1+

**Annexure-2: Rating history for the last three years**

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022
1	Debentures-Non Convertible Debentures	LT	-	-	-	-	-	1)Withdrawn (15-Jul-21)
2	Non-fund-based-Short Term	ST	850.00	CARE A1+	-	1)CARE A1+ (09-Feb-24) 2)CARE A1+ (06-Jul-23)	1)CARE A1+ (13-Jul-22)	1)CARE A1+ (15-Jul-21)
3	Fund-based - LT/ ST-Cash Credit	LT/ST	1650.00	CARE AA+; Negative / CARE A1+	-	1)CARE AA+; Negative / CARE A1+ (09-Feb-24) 2)CARE AA+; Stable / CARE A1+ (06-Jul-23)	1)CARE AA+; Stable / CARE A1+ (13-Jul-22)	1)CARE AA+; Stable / CARE A1+ (15-Jul-21)

4	Debentures-Non Convertible Debentures	LT	-	-	-	-	1)Withdrawn (04-Jan-23) 2)CARE AA+; Stable (13-Jul-22)	1)CARE AA+; Stable (15-Jul-21)
5	Debentures-Non Convertible Debentures	LT	-	-	-	-	1)Withdrawn (13-Jul-22)	1)CARE AA+; Stable (15-Jul-21)
6	Commercial Paper-Commercial Paper (Standalone)	ST	1100.00	CARE A1+	-	1)CARE A1+ (09-Feb-24) 2)CARE A1+ (06-Jul-23)	1)CARE A1+ (13-Jul-22) 2)CARE A1+ (24-Jun-22)	1)CARE A1+ (15-Jul-21)
7	Debentures-Non Convertible Debentures	LT	-	-	-	-	-	1)Withdrawn (15-Jul-21)

LT: Long term; ST: Short term; LT/ST: Long term/Short term

#### **Annexure-3: Detailed explanation of covenants of the rated instruments/facilities: Not applicable**

#### **Annexure-4: Complexity level of the various instruments rated**

Sr. No.	Name of the Instrument	Complexity Level
1	Commercial Paper-Commercial Paper (Standalone)	Simple
2	Fund-based - LT/ ST-Cash Credit	Simple
3	Non-fund-based-Short Term	Simple

#### **Annexure-5: Lender details**

To view the lender wise details of bank facilities please [click here](#)

#### **Annexure-6: List of all the entities consolidated**

Names of Entities Consolidated	Extent of Consolidation	Rationale for Consolidation
UPL Global Business Services Ltd (FKA Shroffs United Chemicals Ltd)	Full	Wholly owned subsidiary
SWAL Corporation Ltd	Full	Wholly owned subsidiary
United Phosphorus (India) LLP	Full	Wholly owned subsidiary
United Phosphorus Global LLP	Full	Wholly owned subsidiary
UPL Sustainable Agri Solutions Ltd (FKA Optima Farm Solutions Ltd)	Full	Wholly owned subsidiary
UPL Europe Ltd	Full	Subsidiary
United Phosphorus Polska Sp.z o.o - Poland	Full	Subsidiary
UPL Benelux B.V.	Full	Subsidiary
Cerexagri B.V.	Full	Subsidiary
UPL Holdings Cooperatief U.A (FKA United Phosphorus Holdings Cooperatief U.A.)	Full	Subsidiary
UPL Holdings BV (FKA United Phosphorus Holdings B.V., Netherlands)	Full	Subsidiary

Names of Entities Consolidated	Extent of Consolidation	Rationale for Consolidation
Decco Worldwide Post-Harvest Holdings Cooperatief U.A.	Full	Subsidiary
Decco Worldwide Post-Harvest Holdings B.V.	Full	Subsidiary
UPL Holdings Brazil B.V. (FKA United Phosphorus Holding, Brazil B.V. )	Full	Subsidiary
UPL Italia S.R.L.	Full	Subsidiary
UPL Iberia, S.A.	Full	Subsidiary
Decco Iberica Postcosecha, S.A.U.	Full	Subsidiary
Transterra Invest, S. L. U.	Full	Subsidiary
Cerexagri S.A.S.	Full	Subsidiary
UPL France	Full	Subsidiary
UPL Switzerland AG (formerly known as United Phosphorus Switzerland Ltd)	Full	Subsidiary
Decco Italia SRL	Full	Subsidiary
Limited Liability Company "UPL"	Full	Subsidiary
Decco Portugal Post Harvest LDA (formerly known as UPL Portugal Unipessoal LDA)	Full	Subsidiary
UPL NA Inc. (formerly known as United Phosphorus Inc.)	Full	Subsidiary
Cerexagri, Inc. (PA)	Full	Subsidiary
UPL Delaware, Inc.	Full	Subsidiary
Decco US Post-Harvest Inc	Full	Subsidiary
RiceCo LLC	Full	Subsidiary
Riceco International, Inc.	Full	Subsidiary
UPL Corporation Ltd	Full	Subsidiary
UPL Management DMCC	Full	Subsidiary
UPL Ltd	Full	Subsidiary
UPL Agro S.A. de C.V.	Full	Subsidiary
Decco PostHarvest Mexico (formerly known as Decco Jifkins Mexico Sapi)	Full	Subsidiary
Uniphos Industria e Comercio de Produtos Quimicos Ltda.	Full	Subsidiary
Upl do Brasil Industria e Comércio de Insumos Agropecuários S.A.	Full	Subsidiary
UPL Costa Rica S.A.	Full	Subsidiary
UPL Bolivia S.R.L	Full	Subsidiary
UPL Paraguay S.A.	Full	Subsidiary
UPL SL Argentina S.A. (Formerly Known as Icona Sanluis S A)	Full	Subsidiary
UPL Argentina S A	Full	Subsidiary
Decco Chile SpA	Full	Subsidiary
UPL Colombia SAS	Full	Subsidiary
United Phosphorus Cayman Ltd	Full	Subsidiary
UP Aviation Ltd	Full	Subsidiary
UPL Australia Pty Ltd (formerly known as UPL Austarlia Ltd)	Full	Subsidiary
UPL Shanghai Ltd	Full	Subsidiary
PT.UPL Indonesia	Full	Subsidiary
PT Catur Agrodaya Mandiri	Full	Subsidiary
UPL Ltd, Hong Kong (formerly known as United Phosphorus Ltd, Hongkong)	Full	Subsidiary
UPL Philippines Inc.	Full	Subsidiary
UPL Vietnam Co. Ltd	Full	Subsidiary
UPL Japan GK (formerly known as UPL Ltd, Japan)	Full	Subsidiary
Anning Decco Fine Chemical Co. Ltd	Full	Subsidiary
UPL Ziraat Ve Kimya Sanayi Ve Ticaret Ltd Sirketi	Full	Subsidiary



Names of Entities Consolidated	Extent of Consolidation	Rationale for Consolidation
UPL Agromed Tohumculuk Sa,Turkey	Full	Subsidiary
Decco Israel Ltd (formerly known as Safepack Products Ltd)	Full	Subsidiary
Citrashine (Pty) Ltd	Full	Subsidiary
Prolong Ltd	Full	Subsidiary
Perrey Participações S.A	Full	Subsidiary
Advanta Netherlands Holding B.V.	Full	Subsidiary
Advanta Semillas SAIC	Full	Subsidiary
Advanta Holdings B.V.	Full	Subsidiary
Advanta Seeds International	Full	Subsidiary
Pacific Seeds Holdings (Thailand) Ltd	Full	Subsidiary
Pacific Seeds (Thai) Ltd	Full	Subsidiary
Advanta Seeds Pty Ltd	Full	Subsidiary
Advanta US LLC (formerly known as Advanta U.S. Inc.)	Full	Subsidiary
Advanta Comercio De Sementes LTDA.	Full	Subsidiary
PT Advanta Seeds Indonesia	Full	Subsidiary
Advanta Seeds DMCC	Full	Subsidiary
UPL Ltd Mauritius (formerly known as UPL Agro Ltd Mauritius)	Full	Subsidiary
UPL Jiangsu Ltd	Full	Subsidiary
Riceco International Bangladesh Ltd	Full	Subsidiary
Uniphos Malaysia Sdn Bhd	Full	Subsidiary
Advanta Seeds Ukraine LLC	Full	Subsidiary
Decco Gida Tarim ve Zirai Ürünler San. Tic A.S.	Full	Subsidiary
Arysta LifeScience America Inc.	Full	Subsidiary
Arysta LifeScience Management Company, LLC	Full	Subsidiary
Arysta LifeScience India Ltd	Full	Subsidiary
Arysta LifeScience Agriservice Pvt Ltd	Full	Subsidiary
UPL Togo SAU (FKA Arysta LifeScience Togo SAU)	Full	Subsidiary
Arysta Agro Pvt Ltd	Full	Subsidiary
GBM USA LLC	Full	Subsidiary
UPL Agrosolutions Canada Inc (formerly known as Arysta LifeScience Canada, Inc.)	Full	Subsidiary
Arysta LifeScience North America, LLC	Full	Subsidiary
Arysta LifeScience NA Holding LLC	Full	Subsidiary
Arysta LifeScience Inc.	Full	Subsidiary
Arysta LifeScience Services LLP	Full	Subsidiary
Arysta LifeScience Benelux SPRL	Full	Subsidiary
Arysta LifeScience (Mauritius) Ltd	Full	Subsidiary
UPL South Africa (Pty) Ltd (formerly known as Arysta LifeScience South Africa (Pty) Ltd)	Full	Subsidiary
Arysta Health and Nutrition Sciences Corporation	Full	Subsidiary
Arysta LifeScience Corporation	Full	Subsidiary
Arysta LifeScience S.A.S.	Full	Subsidiary
Arysta LifeScience Chile S.A.	Full	Subsidiary
Arysta LifeScience Mexico, S.A.de C.V	Full	Subsidiary
Grupo Bioquimico Mexicano, S.A. de C.V.	Full	Subsidiary
Arysta LifeScience UK & Ireland Ltd	Full	Subsidiary



Names of Entities Consolidated	Extent of Consolidation	Rationale for Consolidation
UPL Agricultural Solutions (formerly known as MacDermid Agricultural Solutions Italy Srl)	Full	Subsidiary
UPL Europe Supply Chain GmbH (formerly known as Platform Sales Suisse GmbH)	Full	Subsidiary
UPL Agricultural Solutions Holdings BV (formerly known as MacDermid Agricultural Solutions Holdings BV)	Full	Subsidiary
Netherlands Agricultural Investment Partners LLC	Full	Subsidiary
UPL Bulgaria EOOD (FKA Arysta LifeScience Bulgaria EOOD)	Full	Subsidiary
UPL Agricultural Solutions Romania SRL (FKA Arysta LifeScience Romania SRL)	Full	Subsidiary
Arysta LifeScience Great Britain Ltd	Full	Subsidiary
Arysta LifeScience Netherlands BV	Full	Subsidiary
Arysta LifeScience RUS LLC	Full	Subsidiary
Arysta LifeScience Australia Pty Ltd.	Full	Subsidiary
Arysta-LifeScience Ecuador S.A.	Full	Subsidiary
Arysta LifeScience Ougrée Production Sprl	Full	Subsidiary
UPL Hellas S.A. (formerly known as Arysta LifeScience Hellas S.A. Plant Protection, Nutrition and Other Related Products and Services)	Full	Subsidiary
Naturagri Soluciones, SLU (formerly known as Arysta LifeScience Iberia SLU)	Full	Subsidiary
Arysta LifeScience Switzerland Sarl	Full	Subsidiary
Vetopharma SAS (formerly known as Arysta Animal Health SAS)	Full	Subsidiary
Sci PPWJ	Full	Subsidiary
Vetopharma Iberica SL (formerly known as Santamix Iberica SL, Spain)	Full	Subsidiary
United Phosphorus Global Services Ltd (FKA Arysta LifeScience Global Services Ltd)	Full	Subsidiary
Arysta LifeScience European Investments Ltd	Full	Subsidiary
Arysta LifeScience U.K. Ltd	Full	Subsidiary
Arysta LifeScience U.K. CAD Ltd	Full	Subsidiary
Arysta LifeScience U.K. EUR Ltd	Full	Subsidiary
Arysta LifeScience U.K. JPY Ltd	Full	Subsidiary
Arysta LifeScience U.K. USD Ltd	Full	Subsidiary
Arysta Lifescience U.K. Holdings Ltd	Full	Subsidiary
Arysta LifeScience Japan Holdings Goudou Kaisha	Full	Subsidiary
Arysta LifeScience Cameroun SA	Full	Subsidiary
Callivoire SGFD S.A.	Full	Subsidiary
UPL Egypt Ltd (formerly known as Arysta LifeScience Egypt Ltd)	Full	Subsidiary
Calli Ghana Ltd.	Full	Subsidiary
Arysta LifeScience Kenya Ltd.	Full	Subsidiary
Mali Protection Des Cultures (M.P.C.) SA	Full	Subsidiary
Agrifocus Limitada	Full	Subsidiary
UPL Holdings SA (Pty) Ltd (FKA Arysta LifeScience Holdings SA (Pty) Ltd)	Full	Subsidiary
Anchorprops 39 (Pty) Ltd	Full	Subsidiary
Sidewalk Trading (Pty) Ltd	Full	Subsidiary
Volcano Agrosience (Pty) Ltd	Full	Subsidiary
UPL (T) Ltd (formerly known as Arysta LifeScience Tanzania Ltd)	Full	Subsidiary
Pt. Arysta LifeScience Tirta Indonesia	Full	Subsidiary
UPL Limited Korea (FKA Arysta LifeScience Korea Ltd.)	Full	Subsidiary
Arysta LifeScience Pakistan (Pvt.) LTD.	Full	Subsidiary
Arysta LifeScience Philippines Inc.	Full	Subsidiary
Arysta LifeScience Asia Pte., Ltd.	Full	Subsidiary

Names of Entities Consolidated	Extent of Consolidation	Rationale for Consolidation
Arysta LifeScience (Thailand) Co., Ltd.	Full	Subsidiary
Arysta LifeScience Vietnam Co., Ltd.	Full	Subsidiary
Laboratoires Goëmar SAS	Full	Subsidiary
UPL Czech s.r.o. (FKA Arysta LifeScience Czech s.r.o.)	Full	Subsidiary
UPL Deutschland GmbH, (formerly known as Arysta LifeScience Germany GmbH)	Full	Subsidiary
UPL Hungary Kereskedelmi és Szolgáltató Korlátolt Felelősségű Társaság. (FKA Arysta LifeScience Magyarország Kft.)	Full	Subsidiary
UPL Polska Sp. z o.o (formerly known as Arysta LifeScience Polska Sp. z o.o)	Full	Subsidiary
Betel Reunion S.A.	Full	Subsidiary
Arysta LifeScience Vostok Ltd.	Full	Subsidiary
UPL Slovakia S.R.O ( FKA Arysta LifeScience Slovakia S.R.O.)	Full	Subsidiary
UPL Ukraine LLC (FKA Arysta LifeScience Ukraine LLC)	Full	Subsidiary
UPL Global Ltd (formerly known as Arysta LifeScience Global Limited)	Full	Subsidiary
Arysta LifeScience Colombia S.A.S	Full	Subsidiary
Arysta LifeScience CentroAmerica, S.A.	Full	Subsidiary
Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V.	Full	Subsidiary
Omega Agroindustrial, S.A. de C.V.	Full	Subsidiary
Servicios Agrícolas Mundiales SA de CV	Full	Subsidiary
Arysta LifeScience Paraguay S.R.L.	Full	Subsidiary
Arysta LifeScience Peru S.A.C	Full	Subsidiary
Arysta LifeScience Costa Rica SA.	Full	Subsidiary
Arysta LifeScience de Guatemala, S.A.	Full	Subsidiary
Arysta LifeScience S.R.L.	Full	Subsidiary
Myanmar Arysta LifeScience Co., Ltd.	Full	Subsidiary
Arysta LifeScience U.K. BRL Ltd	Full	Subsidiary
UPL New Zealand Ltd (FKA Etec Crop Solutions Ltd)	Full	Subsidiary
MacDermid Agricultural Solutions Australia Pty Ltd	Full	Subsidiary
Arysta LifeScience Registrations Great Britain Ltd	Full	Subsidiary
Industrias Agriphar SA	Full	Subsidiary
Agripraza Ltda.	Full	Subsidiary
Arysta LifeScience Corporation Republica Dominicana, SRL	Full	Subsidiary
Grupo Bioquímico Mexicano Republica Dominicana SA	Full	Subsidiary
Arvesta Paraguay S.A.	Full	Subsidiary
Arysta Agroquímicos y Fertilizantes Uruguay SA	Full	Subsidiary
Arysta LifeScience U.K. USD-2 Limited	Full	Subsidiary
Industrias Bioquím Centroamericana, Sociedad Anónima	Full	Subsidiary
Bioquím Panama, Sociedad Anónima	Full	Subsidiary
UPL Nicaragua, Sociedad Anónima (FKA Bioquím Nicaragua, Sociedad Anónima)	Full	Subsidiary
Biochemisch Dominicana, Sociedad De Responsabilidad Limitada	Full	Subsidiary
Nutriquím De Guatemala, Sociedad Anónima	Full	Subsidiary
UPL Agro Ltd	Full	Subsidiary
UPL Portugal Unipessoal, Ltda.	Full	Subsidiary
UPL Services LLC	Full	Subsidiary
United Phosphorus Holdings Uk Ltd	Full	Subsidiary
Nurture Agtech Pvt Ltd. (FKA AFS Agtech Pvt. Limited)	Full	Wholly owned subsidiary

Names of Entities Consolidated	Extent of Consolidation	Rationale for Consolidation
Natural Plant Protection Ltd	Full	Subsidiary
Advanta Biotech General Trading Ltd	Full	Subsidiary
UPL Mauritius Ltd	Full	Subsidiary
Hannaford Nurture Farm Exchange Pty Ltd	Full	Subsidiary
UPL Zambia Ltd	Full	Subsidiary
INGEAGRO S.A	Full	Subsidiary
Laoting Yoloo Bio-Technology Co. Ltd	Full	Subsidiary
Decco Holdings UK Ltd	Full	Subsidiary
Advanta Seeds Holdings UK Ltd	Full	Subsidiary
Advanta Holdings US Inc.	Full	Subsidiary
UPL Crop Protection Investments UK Ltd	Full	Subsidiary
UBDS COMERCIO DE PRODUTOS AGROPECUARIOS S.A	Full	Subsidiary
UPL Investments Southern Africa Pty Ltd	Full	Subsidiary
UPL Ltd, Cayman	Full	Subsidiary
UPL Health & Nutrition Science Holdings Ltd	Full	Subsidiary
UPL Animal Health Holdings Ltd	Full	Subsidiary
UPL Investments UK Ltd	Full	Subsidiary
PT Excel Meg Indo	Full	Subsidiary
PT Ace Bio Care	Full	Subsidiary

**Note on the complexity levels of the rated instruments:** CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to [care@careedge.in](mailto:care@careedge.in) for any clarifications.

## Contact us

<b>Media Contact</b>  Mradul Mishra Director <b>CARE Ratings Limited</b> Phone: +91-22-6754 3596 E-mail: <a href="mailto:mradul.mishra@careedge.in">mradul.mishra@careedge.in</a>	<b>Analytical Contacts</b>  Ranjan Sharma Senior Director <b>CARE Ratings Limited</b> Phone: +91-22-6754 3453 E-mail: <a href="mailto:ranjan.sharma@careedge.in">ranjan.sharma@careedge.in</a>
<b>Relationship Contact</b>  Saikat Roy Senior Director <b>CARE Ratings Limited</b> Phone: 91 22 6754 3404 E-mail: <a href="mailto:saikat.roy@careedge.in">saikat.roy@careedge.in</a>	Hardik Manharbhai Shah Director <b>CARE Ratings Limited</b> Phone: +91-22-6754 3591 E-mail: <a href="mailto:hardik.shah@careedge.in">hardik.shah@careedge.in</a>
	Arti Roy Associate Director <b>CARE Ratings Limited</b> Phone: +91-22-6754 3657 E-mail: <a href="mailto:arti.roy@careedge.in">arti.roy@careedge.in</a>

### About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

### Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For the detailed Rationale Report and subscription information,  
please visit [www.careedge.in](http://www.careedge.in)**